Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461].
Journal: The journal of liquid biopsy
Published: June 29, 2026
The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing.
Journal: The journal of liquid biopsy
Published: February 08, 2026
Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort study.
Journal: Frontiers in oncology
Published: January 25, 2026
Risk of central nervous system metastasis and survival in HER2+ positive breast and non-breast cancers.
Journal: Neuro-oncology practice
Published: December 29, 2025
Incidence, management, and outcomes of procarbazine-associated hypersensitivity reactions in patients receiving PCV for lower-grade gliomas.
Journal: Neuro-oncology practice
Published: October 13, 2025
Leveraging Electronic Health Record Tools and Social Work to Improve Advance Care Planning Documentation in Older Adults With Cancer.
Journal: JCO oncology practice
Published: October 10, 2025
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 04, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 15, 2025
Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC.
Journal: JTO clinical and research reports
Published: February 06, 2025
Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy.
Journal: Clinical lung cancer
Published: August 28, 2024
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 13, 2024
Last Updated: 09/26/2026